VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q46905168  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000056.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q46905168‏
024 ‎‡a  0000-0001-9565-3845‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q46905168‏
100 0 ‎‡a  Jonathan M Payne‏ ‎‡9  ast‏ ‎‡9  es‏ ‎‡9  sl‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Jonathan M Payne‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Jonathan M Payne‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's Assessment and management of tic disorders and Tourette syndrome by Australian paediatricians‏
670 ‎‡a  Author's Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior‏
670 ‎‡a  Author's Attention to faces in social context in children with neurofibromatosis type 1‏
670 ‎‡a  Author's Attentional load attenuates synaesthetic priming effects in grapheme-colour synaesthesia‏
670 ‎‡a  Author's Atypical Local Interference Affects Global Processing in Children with Neurofibromatosis Type 1‏
670 ‎‡a  Author's Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden‏
670 ‎‡a  Author's Autism spectrum disorder symptomatology in children with neurofibromatosis type 1.‏
670 ‎‡a  Author's Brain structure and function in neurofibromatosis type 1: current concepts and future directions.‏
670 ‎‡a  Author's Bridging the Gap Between Mouse Behavior and Human Cognition in Neurofibromatosis Type 1‏
670 ‎‡a  Author's Chronic tic disorders in children with ADHD.‏
670 ‎‡a  Author's Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1‏
670 ‎‡a  Author's Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1.‏
670 ‎‡a  Author's Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).‏
670 ‎‡a  Author's Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?‏
670 ‎‡a  Author's Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial‏
670 ‎‡a  Author's Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial‏
670 ‎‡a  Author's Facial emotion recognition, face scan paths, and face perception in children with neurofibromatosis type 1.‏
670 ‎‡a  Author's Fast and slow parietal pathways mediate spatial attention.‏
670 ‎‡a  Author's Impaired engagement of the ventral attention system in neurofibromatosis type 1.‏
670 ‎‡a  Author's Longitudinal assessment of cognition and T2-hyperintensities in NF1: An 18-year study‏
670 ‎‡a  Author's Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention‏
670 ‎‡a  Author's Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.‏
670 ‎‡a  Author's Parietal disruption impairs reflexive spatial attention within and between sensory modalities‏
670 ‎‡a  Author's Phonics Training Improves Reading in Children with Neurofibromatosis Type 1: A Prospective Intervention Trial‏
670 ‎‡a  Author's Preliteracy impairments in children with neurofibromatosis type 1‏
670 ‎‡a  Author's Profiling the Word Reading Abilities of School-Age Children with Neurofibromatosis Type 1‏
670 ‎‡a  Author's Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.‏
670 ‎‡a  Author's Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1.‏
670 ‎‡a  Author's Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1‏
670 ‎‡a  Author's Skeletal muscle and motor deficits in Neurofibromatosis Type 1.‏
670 ‎‡a  Author's Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis‏
670 ‎‡a  Author's Social functioning in adults with neurofibromatosis type 1.‏
670 ‎‡a  Author's Social skills and autism spectrum disorder symptoms in children with neurofibromatosis type 1: evidence for clinical trial outcomes‏
670 ‎‡a  Author's The genetic and neuroanatomical basis of social dysfunction: lessons from neurofibromatosis type 1.‏
670 ‎‡a  Author's The impact of ADHD on the cognitive and academic functioning of children with NF1.‏
670 ‎‡a  Author's The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study.‏
670 ‎‡a  Author's Theory of mind in children with Neurofibromatosis Type 1.‏
670 ‎‡a  Author's Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study‏
670 ‎‡a  Author's Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1‏
670 ‎‡a  Author's Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge.‏
909 ‎‡a  (orcid) 0000000195653845‏ ‎‡9  1‏
919 ‎‡a  profilingthewordreadingabilitiesofschoolagechildrenwithneurofibromatosistype1‏ ‎‡A  Profiling the Word Reading Abilities of School-Age Children with Neurofibromatosis Type 1‏ ‎‡9  1‏
919 ‎‡a  doescannabidiolreduceseverebehaviouralproblemsinchildrenwithintellectualdisabilitystudyprotocolforapilotsinglesitephase12randomisedplacebocontrolledtrial‏ ‎‡A  Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial‏ ‎‡9  1‏
919 ‎‡a  effectsofmethylphenidateoncognitionandbehaviourinchildrenwithneurofibromatosistype1astudyprotocolforarandomisedplacebocontrolledcrossovertrial‏ ‎‡A  Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial‏ ‎‡9  1‏
919 ‎‡a  fastandslowparietalpathwaysmediatespatialattention‏ ‎‡A  Fast and slow parietal pathways mediate spatial attention.‏ ‎‡9  1‏
919 ‎‡a  randomizedplacebocontrolledstudyoflovastatininchildrenwithneurofibromatosistype1‏ ‎‡A  Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  relationshipbetweencognitivedysfunctiongaitandmotorimpairmentinchildrenandadolescentswithneurofibromatosistype1‏ ‎‡A  Relationship between cognitive dysfunction, gait, and motor impairment in children and adolescents with neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  attentiontofacesinsocialcontextinchildrenwithneurofibromatosistype1‏ ‎‡A  Attention to faces in social context in children with neurofibromatosis type 1‏ ‎‡9  1‏
919 ‎‡a  attentionalloadattenuatessynaestheticprimingeffectsingraphemecoloursynaesthesia‏ ‎‡A  Attentional load attenuates synaesthetic priming effects in grapheme-colour synaesthesia‏ ‎‡9  1‏
919 ‎‡a  reproducibilityofcognitiveendpointsinclinicaltrialslessonsfromneurofibromatosistype1‏ ‎‡A  Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1‏ ‎‡9  1‏
919 ‎‡a  skeletalmuscleandmotordeficitsinneurofibromatosistype1‏ ‎‡A  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.‏ ‎‡9  1‏
919 ‎‡a  socialfunctionandautismspectrumdisorderinchildrenandadultswithneurofibromatosistype1asystematicreviewandmetaanalysis‏ ‎‡A  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis‏ ‎‡9  1‏
919 ‎‡a  socialfunctioninginadultswithneurofibromatosistype1‏ ‎‡A  Social functioning in adults with neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  socialskillsandautismspectrumdisordersymptomsinchildrenwithneurofibromatosistype1evidenceforclinicaltrialoutcomes‏ ‎‡A  Social skills and autism spectrum disorder symptoms in children with neurofibromatosis type 1: evidence for clinical trial outcomes‏ ‎‡9  1‏
919 ‎‡a  geneticandneuroanatomicalbasisofsocialdysfunctionlessonsfromneurofibromatosistype1‏ ‎‡A  The genetic and neuroanatomical basis of social dysfunction: lessons from neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  atypicallocalinterferenceaffectsglobalprocessinginchildrenwithneurofibromatosistype1‏ ‎‡A  Atypical Local Interference Affects Global Processing in Children with Neurofibromatosis Type 1‏ ‎‡9  1‏
919 ‎‡a  impactofadhdonthecognitiveandacademicfunctioningofchildrenwithnf1‏ ‎‡A  The impact of ADHD on the cognitive and academic functioning of children with NF1.‏ ‎‡9  1‏
919 ‎‡a  neuralbasisofdeficientresponseinhibitioninchildrenwithneurofibromatosistype1evidencefromafunctionalmristudy‏ ‎‡A  The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study.‏ ‎‡9  1‏
919 ‎‡a  autisminneurofibromatosistype1misuseofcovariancetodismissautistictraitburden‏ ‎‡A  Autism in neurofibromatosis type 1: misuse of covariance to dismiss autistic trait burden‏ ‎‡9  1‏
919 ‎‡a  cognitionadhdsymptomsandfunctionalimpairmentinchildrenandadolescentswithneurofibromatosistype1‏ ‎‡A  Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1‏ ‎‡9  1‏
919 ‎‡a  facialemotionrecognitionfacescanpathsandfaceperceptioninchildrenwithneurofibromatosistype1‏ ‎‡A  Facial emotion recognition, face scan paths, and face perception in children with neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  autismspectrumdisordersymptomatologyinchildrenwithneurofibromatosistype1‏ ‎‡A  Autism spectrum disorder symptomatology in children with neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  bridgingthegapbetweenmousebehaviorandhumancognitioninneurofibromatosistype1‏ ‎‡A  Bridging the Gap Between Mouse Behavior and Human Cognition in Neurofibromatosis Type 1‏ ‎‡9  1‏
919 ‎‡a  theoryofmindinchildrenwithneurofibromatosistype1‏ ‎‡A  Theory of mind in children with Neurofibromatosis Type 1.‏ ‎‡9  1‏
919 ‎‡a  understandingautismspectrumdisorderandsocialfunctioninginchildrenwithneurofibromatosistype1protocolforacrosssectionalmultimodalstudy‏ ‎‡A  Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study‏ ‎‡9  1‏
919 ‎‡a  visualspatiallearningoutcomesforclinicaltrialsinneurofibromatosistype1‏ ‎‡A  Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1‏ ‎‡9  1‏
919 ‎‡a  youngaustralianadultswithnf1havepooraccesstohealthcarehighcomplicationratesandlimiteddiseaseknowledge‏ ‎‡A  Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge.‏ ‎‡9  1‏
919 ‎‡a  chronicticdisordersinchildrenwithadhd‏ ‎‡A  Chronic tic disorders in children with ADHD.‏ ‎‡9  1‏
919 ‎‡a  corpuscallosummorphologyanditsrelationshiptocognitivefunctioninneurofibromatosistype1‏ ‎‡A  Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  diseaseburdenandsymptomstructureofautisminneurofibromatosistype1astudyoftheinternationalnf1asdconsortiumteaminfact‏ ‎‡A  Disease Burden and Symptom Structure of Autism in Neurofibromatosis Type 1: A Study of the International NF1-ASD Consortium Team (INFACT).‏ ‎‡9  1‏
919 ‎‡a  doesattentiondeficithyperactivitydisorderexacerbateexecutivedysfunctioninchildrenwithneurofibromatosistype1‏ ‎‡A  Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1?‏ ‎‡9  1‏
919 ‎‡a  assessmentofexecutivefunctionandattentioninchildrenwithneurofibromatosistype1relationshipsbetweencognitivemeasuresandrealworldbehavior‏ ‎‡A  Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior‏ ‎‡9  1‏
919 ‎‡a  longitudinalassessmentofcognitionandt2hyperintensitiesinnf1an18yearstudy‏ ‎‡A  Longitudinal assessment of cognition and T2-hyperintensities in NF1: An 18-year study‏ ‎‡9  1‏
919 ‎‡a  neurocognitiveoutcomesinneurofibromatosisclinicaltrialsrecommendationsforthedomainofattention‏ ‎‡A  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention‏ ‎‡9  1‏
919 ‎‡a  pairedassociatelearninginchildrenwithneurofibromatosistype1implicationsforclinicaltrials‏ ‎‡A  Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials.‏ ‎‡9  1‏
919 ‎‡a  parietaldisruptionimpairsreflexivespatialattentionwithinandbetweensensorymodalities‏ ‎‡A  Parietal disruption impairs reflexive spatial attention within and between sensory modalities‏ ‎‡9  1‏
919 ‎‡a  assessmentandmanagementofticdisordersandtourettesyndromebyaustralianpaediatricians‏ ‎‡A  Assessment and management of tic disorders and Tourette syndrome by Australian paediatricians‏ ‎‡9  1‏
919 ‎‡a  impairedengagementoftheventralattentionsysteminneurofibromatosistype1‏ ‎‡A  Impaired engagement of the ventral attention system in neurofibromatosis type 1.‏ ‎‡9  1‏
919 ‎‡a  phonicstrainingimprovesreadinginchildrenwithneurofibromatosistype1aprospectiveinterventiontrial‏ ‎‡A  Phonics Training Improves Reading in Children with Neurofibromatosis Type 1: A Prospective Intervention Trial‏ ‎‡9  1‏
919 ‎‡a  preliteracyimpairmentsinchildrenwithneurofibromatosistype1‏ ‎‡A  Preliteracy impairments in children with neurofibromatosis type 1‏ ‎‡9  1‏
919 ‎‡a  brainstructureandfunctioninneurofibromatosistype1currentconceptsandfuturedirections‏ ‎‡A  Brain structure and function in neurofibromatosis type 1: current concepts and future directions.‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  CAOONL|ncf11481195‏
996 ‎‡2  ISNI|0000000083716610‏
996 ‎‡2  SUDOC|081610882‏
996 ‎‡2  LC|n 2018009305‏
996 ‎‡2  BIBSYS|90308225‏
996 ‎‡2  DNB|1269915258‏
996 ‎‡2  NTA|156676354‏
996 ‎‡2  LC|nb2021002381‏
996 ‎‡2  ISNI|0000000082383279‏
996 ‎‡2  J9U|987007444653105171‏
996 ‎‡2  RERO|A024521735‏
996 ‎‡2  NTA|070056323‏
996 ‎‡2  LC|nb2019022664‏
996 ‎‡2  DNB|1055600817‏
996 ‎‡2  ISNI|0000000040832961‏
996 ‎‡2  ISNI|0000000049554718‏
996 ‎‡2  LC|n 88065214‏
996 ‎‡2  CAOONL|ncf13692847‏
996 ‎‡2  NUKAT|n 2011244354‏
996 ‎‡2  ISNI|0000000500275351‏
996 ‎‡2  BNF|14214534‏
996 ‎‡2  BNF|14214531‏
996 ‎‡2  ISNI|0000000113367176‏
996 ‎‡2  CAOONL|ncf11263702‏
996 ‎‡2  CAOONL|ncf10907505‏
996 ‎‡2  LC|nr 95035874‏
996 ‎‡2  NTA|074821733‏
996 ‎‡2  CAOONL|ncf10907507‏
996 ‎‡2  NUKAT|n 2008136883‏
996 ‎‡2  PLWABN|9810540120805606‏
996 ‎‡2  LNB|LNC10-000259193‏
996 ‎‡2  NTA|216677645‏
996 ‎‡2  LC|no2009176195‏
996 ‎‡2  BIBSYS|90870015‏
996 ‎‡2  NKC|xx0182043‏
996 ‎‡2  SUDOC|085979899‏
996 ‎‡2  N6I|vtls000278033‏
996 ‎‡2  JPG|500090292‏
996 ‎‡2  LC|no2021145567‏
996 ‎‡2  ISNI|0000000496813611‏
996 ‎‡2  LC|no2022092720‏
996 ‎‡2  NLA|000035413337‏
996 ‎‡2  CAOONL|ncf11661317‏
996 ‎‡2  RERO|A009227546‏
996 ‎‡2  DNB|142990620‏
996 ‎‡2  ISNI|0000000116901901‏
996 ‎‡2  ISNI|0000000045286963‏
996 ‎‡2  LIH|LNB:C_i_L_a_;=B_p_‏
996 ‎‡2  SUDOC|116484934‏
996 ‎‡2  SUDOC|230812139‏
996 ‎‡2  ISNI|000000004393420X‏
996 ‎‡2  ISNI|0000000121184126‏
996 ‎‡2  DNB|105608104X‏
996 ‎‡2  BIBSYS|4065785‏
996 ‎‡2  LIH|LNB:CGS3;=_y__h_‏
996 ‎‡2  CAOONL|ncf10609975‏
996 ‎‡2  DE633|pe30032344‏
996 ‎‡2  ISNI|0000000108751739‏
996 ‎‡2  LC|n 92027249‏
996 ‎‡2  LC|no2008049952‏
996 ‎‡2  NTA|417358660‏
996 ‎‡2  NTA|363920722‏
996 ‎‡2  ISNI|0000000040481671‏
996 ‎‡2  NII|DA01270554‏
996 ‎‡2  LC|n 83028706‏
996 ‎‡2  ISNI|0000000060023782‏
996 ‎‡2  LC|n 95013092‏
996 ‎‡2  ISNI|0000000128155395‏
996 ‎‡2  NTA|180721429‏
996 ‎‡2  NTA|339709162‏
996 ‎‡2  LC|no2017032975‏
996 ‎‡2  BNF|13482723‏
996 ‎‡2  NUKAT|n 2018049323‏
996 ‎‡2  BNC|981058528550706706‏
996 ‎‡2  SUDOC|153275472‏
996 ‎‡2  LC|nr2006002320‏
996 ‎‡2  LC|nb 98090165‏
996 ‎‡2  ISNI|0000000022291276‏
996 ‎‡2  LC|no2019174842‏
996 ‎‡2  PLWABN|9810632338105606‏
996 ‎‡2  LC|no 96043595‏
996 ‎‡2  BNE|XX1380070‏
996 ‎‡2  NUKAT|n 2009096276‏
996 ‎‡2  ISNI|0000000048913942‏
996 ‎‡2  NTA|27084676X‏
996 ‎‡2  ISNI|0000000453149335‏
996 ‎‡2  J9U|987007419299505171‏
996 ‎‡2  LC|nr 97036667‏
996 ‎‡2  RERO|A014167356‏
996 ‎‡2  BAV|495_308150‏
996 ‎‡2  DNB|134606116‏
996 ‎‡2  B2Q|0000287977‏
996 ‎‡2  SUDOC|264483715‏
996 ‎‡2  NII|DA19597168‏
996 ‎‡2  ISNI|0000000070340669‏
996 ‎‡2  LC|no2014044941‏
996 ‎‡2  ISNI|0000000460259444‏
996 ‎‡2  SUDOC|033130582‏
996 ‎‡2  LC|no2019126177‏
996 ‎‡2  NTA|301924465‏
996 ‎‡2  NTA|068983204‏
996 ‎‡2  NII|DA10620216‏
996 ‎‡2  PLWABN|9810651293005606‏
996 ‎‡2  DNB|1145847390‏
996 ‎‡2  LC|n 90608108‏
996 ‎‡2  NTA|183259882‏
996 ‎‡2  NII|DA0912262X‏
996 ‎‡2  LC|no 00018005‏
996 ‎‡2  ISNI|0000000082283622‏
996 ‎‡2  B2Q|0000865148‏
996 ‎‡2  SUDOC|178277754‏
996 ‎‡2  NUKAT|n 01019777‏
996 ‎‡2  NLA|000035810405‏
996 ‎‡2  DBC|87097968806046‏
996 ‎‡2  LC|n 92056740‏
996 ‎‡2  LC|n 50007764‏
996 ‎‡2  LC|no2004023150‏
996 ‎‡2  NTA|315736127‏
996 ‎‡2  LC|nr 93008634‏
996 ‎‡2  ISNI|0000000093829133‏
996 ‎‡2  BIBSYS|1615358753214‏
996 ‎‡2  J9U|987007342489405171‏
996 ‎‡2  BIBSYS|3063477‏
996 ‎‡2  CAOONL|ncf10668545‏
996 ‎‡2  ISNI|0000000108791589‏
996 ‎‡2  BIBSYS|90082658‏
996 ‎‡2  BNF|16407380‏
996 ‎‡2  NII|DA13682209‏
996 ‎‡2  LC|n 2006034994‏
996 ‎‡2  LC|no 00103353‏
996 ‎‡2  J9U|987007451900305171‏
996 ‎‡2  ISNI|0000000108592336‏
996 ‎‡2  ISNI|0000000355141970‏
996 ‎‡2  ISNI|0000000057913725‏
996 ‎‡2  NKC|mub2015893488‏
996 ‎‡2  J9U|987007281917005171‏
996 ‎‡2  LC|no2011003362‏
996 ‎‡2  LC|n 82219254‏
996 ‎‡2  CAOONL|ncf13784973‏
996 ‎‡2  BNF|12686513‏
996 ‎‡2  ISNI|0000000139098330‏
996 ‎‡2  LC|n 2014076906‏
996 ‎‡2  CAOONL|ncf11707395‏
996 ‎‡2  LC|nr 92042195‏
996 ‎‡2  DNB|11879003X‏
996 ‎‡2  ISNI|000000038442833X‏
996 ‎‡2  ISNI|0000000033653033‏
996 ‎‡2  LC|no2012139054‏
996 ‎‡2  CAOONL|ncf10907506‏
996 ‎‡2  NTA|070299544‏
996 ‎‡2  BNF|16113590‏
996 ‎‡2  ISNI|0000000001754331‏
996 ‎‡2  LC|n 2014189790‏
996 ‎‡2  LC|no2023045213‏
996 ‎‡2  SUDOC|080677312‏
996 ‎‡2  NII|DA07918796‏
996 ‎‡2  SUDOC|189783303‏
996 ‎‡2  DNB|137875193‏
996 ‎‡2  BIBSYS|90202400‏
996 ‎‡2  SUDOC|031007341‏
996 ‎‡2  LC|n 90641348‏
996 ‎‡2  SUDOC|181047977‏
996 ‎‡2  NLA|000035413326‏
996 ‎‡2  BIBSYS|90268228‏
996 ‎‡2  ISNI|0000000451401197‏
996 ‎‡2  NII|DA04718032‏
996 ‎‡2  LC|no2008018702‏
996 ‎‡2  LC|n 94067851‏
996 ‎‡2  LC|n 80082267‏
996 ‎‡2  DNB|139023313‏
996 ‎‡2  NUKAT|n 2013009380‏
996 ‎‡2  B2Q|0001644492‏
996 ‎‡2  J9U|987007388819805171‏
996 ‎‡2  LC|n 2008067029‏
996 ‎‡2  DNB|124526322‏
996 ‎‡2  ISNI|0000000500902781‏
996 ‎‡2  ISNI|0000000038023356‏
996 ‎‡2  DNB|125841639‏
996 ‎‡2  CAOONL|ncf11500273‏
996 ‎‡2  LIH|LNB:B_d_T_a_;=B_r_‏
996 ‎‡2  NUKAT|n 2009086889‏
996 ‎‡2  RERO|A024722173‏
996 ‎‡2  N6I|vtls000068426‏
996 ‎‡2  LC|no 89013012‏
996 ‎‡2  ISNI|0000000077294861‏
996 ‎‡2  NUKAT|n 2016085729‏
996 ‎‡2  N6I|vtls000280816‏
996 ‎‡2  LC|no2014003284‏
996 ‎‡2  LC|nb2021006992‏
996 ‎‡2  ISNI|0000000117637014‏
996 ‎‡2  BNF|12767407‏
996 ‎‡2  ISNI|0000000440093360‏
996 ‎‡2  BNF|13322980‏
996 ‎‡2  RERO|A025639824‏
996 ‎‡2  LC|no2013028686‏
996 ‎‡2  LC|nr 94043273‏
996 ‎‡2  SUDOC|133191206‏
996 ‎‡2  LC|no2009027311‏
996 ‎‡2  BIBSYS|1054183‏
996 ‎‡2  ISNI|0000000080809694‏
996 ‎‡2  CAOONL|ncf11279297‏
996 ‎‡2  LC|nb2012020064‏
996 ‎‡2  NTA|068232160‏
996 ‎‡2  SUDOC|261404636‏
996 ‎‡2  LC|nb2021005675‏
996 ‎‡2  NTA|339714034‏
996 ‎‡2  ISNI|0000000048981478‏
996 ‎‡2  N6I|vtls001409957‏
996 ‎‡2  ISNI|0000000063835866‏
996 ‎‡2  ISNI|0000000033353882‏
996 ‎‡2  DNB|1055495525‏
996 ‎‡2  ISNI|000000005942794X‏
996 ‎‡2  ISNI|0000000402483923‏
996 ‎‡2  ISNI|0000000050146607‏
996 ‎‡2  ISNI|0000000035946833‏
996 ‎‡2  LC|n 81066513‏
996 ‎‡2  ISNI|000000004197315X‏
996 ‎‡2  LC|no2022058419‏
996 ‎‡2  ISNI|0000000081702100‏
996 ‎‡2  LIH|LNB:CFC_j_;=BM‏
996 ‎‡2  NKC|xx0032895‏
996 ‎‡2  BNE|XX4930042‏
996 ‎‡2  B2Q|0000077978‏
996 ‎‡2  DNB|1014988462‏
996 ‎‡2  LC|no2023090369‏
996 ‎‡2  PLWABN|9810643966305606‏
996 ‎‡2  LC|nr2001011614‏
996 ‎‡2  LC|nb2017024527‏
996 ‎‡2  NTA|071750878‏
996 ‎‡2  LC|n 87939164‏
996 ‎‡2  LC|n 00122506‏
996 ‎‡2  EGAXA|vtls002636631‏
996 ‎‡2  CAOONL|ncf12032057‏
996 ‎‡2  DNB|1053188986‏
996 ‎‡2  DNB|1067433163‏
996 ‎‡2  N6I|vtls001412238‏
996 ‎‡2  LC|no 94021807‏
996 ‎‡2  ISNI|0000000067268627‏
996 ‎‡2  J9U|987007266464905171‏
996 ‎‡2  BLBNB|000316753‏
996 ‎‡2  NUKAT|n 00026169‏
996 ‎‡2  SUDOC|197385567‏
996 ‎‡2  DNB|134085116‏
996 ‎‡2  SUDOC|245358854‏
996 ‎‡2  UAE|Mill_a10002288‏
996 ‎‡2  DNB|171386574‏
996 ‎‡2  LC|n 95056998‏
996 ‎‡2  CAOONL|ncf10282057‏
996 ‎‡2  BNF|14555005‏
996 ‎‡2  LC|nr 97035087‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏